Rigel Pharmaceuticals Inc. appointed Dean Schorno as executive vice president and CFO.
Schorno previously served as CFO and head of operations at 23andMe Inc., which operates as a personal genetics company.
Rigel Pharmaceuticals appoints CFO
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Rigel Pharmaceuticals Inc. appointed Dean Schorno as executive vice president and CFO.
Schorno previously served as CFO and head of operations at 23andMe Inc., which operates as a personal genetics company.